7-(2,6-Dimethyl-phenyl)-benzo[1,2,4]triazin-3-ylamine | 677297-90-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 7-(2,6-Dimethyl-phenyl)-benzo[1,2,4]triazin-3-ylamine
• 英文别名: 7-(2,6-dimethylphenyl)-1,2,4-benzotriazin-3-amine
• CAS: 677297-90-4
• 化学式: C₁₅H₁₄N₄
• 分子量: 250.303
• InChiKey: CFKCMVCEHGIRLA-UHFFFAOYSA-N

物化性质

• 沸点：
  438.2±53.0 °C(Predicted)
• 密度：
  1.230±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  64.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-(2,6-Dimethyl-phenyl)-benzo[1,2,4]triazin-3-ylamine 、 氨基磺酸 以 苯胺 为溶剂， 反应 16.0h， 生成 [7-(2,6-dimethyl-phenyl)-benzo[1,2,4]triazin-3-yl]-phenyl-amine
  参考文献：
  名称：

  Vasculostatic agents and methods of use thereof

  摘要：

  提供了用于治疗与血管稳定性受损相关的疾病的组合物和方法。发明的方法和组合物可用于治疗各种疾病，例如中风、心肌梗死、癌症、缺血/再灌注损伤、自身免疫疾病如类风湿性关节炎、眼部疾病如视网膜病变或黄斑变性或其他玻璃体视网膜疾病、炎症性疾病、血管渗漏综合征、水肿、移植排斥反应、成人/急性呼吸窘迫综合征（ARDS）等。

  公开号：

  US20040167198A1
• 作为产物：
  描述：

  4-溴-2-硝基苯胺 在 镍 盐酸 、 sodium hydroxide 、 四(三苯基膦)钯 、 氢气 、 potassium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 反应 9.0h， 生成 7-(2,6-Dimethyl-phenyl)-benzo[1,2,4]triazin-3-ylamine
  参考文献：
  名称：

  Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine—a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays

  摘要：

  We describe the identification of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-l-ylethoxy)phenyl]amine (3), a potent, orally active Src inhibitor with desirable PK properties, demonstrated activity in human tumor cell lines and in animal models of tumor growth. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.11.006

文献信息

• Benzotriazine inhibitors of kinases
  申请人：Noronha Glenn

  公开号：US20050245524A1

  公开（公告）日：2005-11-03

  The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.

  该发明提供了具有化学式（I）的苯并三唑化合物。该发明的苯并三唑化合物能够抑制激酶，如Src激酶家族成员，以及其他特定的受体和非受体激酶。
• VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF
  申请人：Wrasidlo Wolfgang

  公开号：US20100278811A1

  公开（公告）日：2010-11-04

  Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.

  本发明提供了用于治疗与血管稳态受损相关的疾病的组合物和方法。本发明的方法和组合物可用于治疗各种疾病，例如中风、心肌梗塞、癌症、缺血/再灌注损伤、自身免疫疾病，如类风湿性关节炎、眼部疾病，如视网膜病变或黄斑变性或其他玻璃体视网膜疾病、炎症性疾病、血管渗漏综合症、水肿、移植排斥、成人/急性呼吸窘迫综合症（ARDS）等。
• Vasculostatic Agents and Methods of Use Thereof
  申请人：Wrasidlo Wolfgang

  公开号：US20100330030A1

  公开（公告）日：2010-12-30

  Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.

  提供用于治疗与血管稳定性受损相关的疾病的组合物和方法。发明的方法和组合物可用于治疗多种疾病，包括中风、心肌梗塞、癌症、缺血/再灌注损伤、自身免疫疾病如类风湿性关节炎、眼部疾病如视网膜病变或黄斑变性或其他玻璃体视网膜疾病、炎症性疾病、血管渗漏综合征、水肿、移植排斥、成人/急性呼吸窘迫综合征（ARDS）等。
• Discovery and preliminary structure–activity relationship studies of novel benzotriazine based compounds as Src inhibitors
  作者：Glenn Noronha、Kathy Barrett、Jianguo Cao、Elena Dneprovskaia、Richard Fine、Xianchang Gong、Colleen Gritzen、John Hood、Xinshan Kang、Boris Klebansky、G. Li、W. Liao、Dan Lohse、Chi Ching Mak、Andrew McPherson、Moorthy S.S. Palanki、Ved P. Pathak、Joel Renick、Richard Soll、Ute Splittgerber、Wolfgang Wrasidlo、Binqi Zeng、Ningning Zhao、Y. Zhou

  DOI：10.1016/j.bmcl.2006.08.035

  日期：2006.11

  We report the discovery and preliminary SAR studies of a series of structurally novel benzotriazine core based small molecules as inhibitors of Src kinase. To the best of our knowledge, benzotriazine template based compounds have not been reported as kinase inhibitors. The 3-(2-(1-pyrrolidinyl)ethoxy)phenyI analogue (43) was identified as one of the most potent inhibitors of Src kinase. (c) 2006 Elsevier Ltd. All rights reserved.
• EP1549614A4
  申请人：——

  公开号：EP1549614A4

  公开（公告）日：2008-04-16